Bristol-Myers Squibb and Pfizer to present new Eliquis (apixaban) data at ESC

224

Bristol-Myers Squibb Company and Pfizer have announced that they will present 14 abstracts (oral and poster presentations) at the ESC Congress 2014, organised by the European Society of Cardiology, to be held 30 August to 4 September in Barcelona, Spain. The new clinical trial data and GHEOR analyses assessing cost effectiveness and real-world use reinforcing the alliance’s commitment to the ongoing analysis of Eliquis in both the NVAF and VTE patient populations.

The complete list of Bristol-Myers Squibb/Pfizer alliance presentations is included below. Abstracts can be accessed on the ESC Congress 2014 website.

Title

Presenting Author/Type

Date/Time (CEST)

Location/Session

ARISTOTLE Biomarker Analyses

Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial

Session: Posters Sessions

Asberg, S/

Poster

31 Aug

14:00 – 18:00

Poster area – Central Village

A new biomarker based risk score for predicting major bleeding in atrial fibrillation – the ABC (age, biomarkers, current disease) risk score

Session: Prediction and Prevention of Atrial fibrillation (AF)

Hijazi, Z/

Moderated Poster

31 Aug

15:38 – 15:47

Moderated

poster corner- Central Village

The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment

Session: Atrial Fibrillation: How to improve prognosis?

Christersson, C/

Abstract Session

2 Sep

08:45 – 09:00

Tbilisi – Village 7

Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation

Session: Posters Sessions

Aulin, J/

Poster

2 Sep

14:00 – 18:00

Poster area – Central Village

AMPLIFY and AMPLIFY-EXT

Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial

Session: Posters Sessions

Agnelli, G/

Poster

2 Sep

08:30 – 12:30

Poster area – Central Village

Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial

Session: Refining antithrombotic therapy in coronary artery disease

Cohen, A/

Moderated Poster

31 Aug

10:00 – 10:08

Moderated poster corner – Central Village

Predictors of hospitalization during extended treatment of venous thromboembolism in the AMPLIFY-EXT trial

Session: Acute Pulmonary Embolism

Cohen, A/

Oral

30 Aug

11:18 – 11:36

Cairo Village

Indirect Treatment Comparisons and Economic Value Analyses

Efficacy and safety of apixaban versus edoxaban for stroke prevention in NVAF patients: an indirect treatment analysis

Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use

Lip GYH/

Oral

2 Sep

11:00 – 11:15

Vilinius Village

Potential impact of apixaban on formulary budget and clinical outcomes in non-valvular atrial fibrillation patients

Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use

Kachroo, S/

Oral

2 Sep

11:30 – 11:45

Vilinius Village

Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation

Session: Posters Sessions

Lip GYH/

Poster

2 Sep

14:00 – 18:00

Central Village

Comparison of apixaban, dabigatran and rivaroxaban in the acute treatment and prevention of venous thromboembolism: systematic review and network meta-analysis

Session: Venous Thromboembolism: What’s New

Cohen, A/

Oral

2 Sep

17:15 – 17:30

Tbilisi Village

Cost-effectiveness of apixaban compared to other anticoagulants for the acute (6-month) treatment of venous thromboembolism

Session: Venous Thromboembolism: What’s New

Lanitis, T/

Oral

2 Sep

16:45 – 17:00

Tbilisi Village

Real World Data Analyses

Real world discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tell of first 200 days

Session: Novel Oral Anticoagulants: Trials, Costs and Real Life Use

Phatak, H/

Oral

2 Sep

12:15 – 12:30

Vilinius Village

Warfarin discontinuation in patients with unprovoked venous thromboembolism: a large U.S. insurance database analysis

Session: Posters Sessions

Liu JXC/

Poster

2 Sep

8:30 to 12:00

Central Village

(Visited 41 times, 1 visits today)